Percorrer por autor "Hasmucrai, Direndra"
A mostrar 1 - 1 de 1
Resultados por página
Opções de ordenação
- Real-world challenges in first-line treatment of metastatic EGFR-mutated non-small cell lung cancerPublication . Barreto, Inês; Figueiredo, Sara; Tonin, Fernanda; Vilariça, Ana Sofia; Hasmucrai, Direndra; Alves, PaulaOsimertinib, a third-generation tyrosine kinase inhibitor (TKI), was recently introduced in several countries, including Portugal (reimbursement in 2021), as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating proto-oncogene epidermal growth factor receptor mutations (EGFRm), after showing significant efficacy and safety when used in patients with EGFR-T790M resistance mutations. However, despite advances in personalized target treatments in this field, challenges regarding patients’ journey (e.g., therapy selection criteria, EGFR-TKI optimal sequencing, treatment beyond second-line) still exist.